Citigroup’s Hemab Therapeutics COAG Stock Holding History

Citigroup’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.9K	Buy	+2,095	New	+$57.8K	﹤0.01%	4819

Other funds holding COAG

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Citigroup's COAG Position: Q2 2026 in Review

Citigroup opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 2,095 shares worth $76.9K. The stake represents ﹤0.01% of the portfolio and ranks #4819 among its holdings.

4 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

Citigroup held 2,095 shares of Hemab Therapeutics worth $76.9K as of Q2 2026.
Hemab Therapeutics was a new Citigroup position in Q2 2026.
Hemab Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4819 holding.
4 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.